Why some people with chronic lymphocytic leukemia respond to BTK degrader drugs
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
This project collects blood, bone marrow, or leftover lymph node samples from adults with CLL who are candidates for or have received BTK degrader drugs to see why some people respond and others become resistant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 14 sites (Angers and 13 other locations) |
| Trial ID | NCT07099443 on ClinicalTrials.gov |
What this trial studies
This observational cohort creates a biobank of blood, bone marrow and residual lymph node biopsy samples from CLL patients who are candidates for or have been exposed to BTK degraders. Extra samples are collected alongside routine clinical care after informed consent, with no experimental treatment assigned by the protocol. Laboratory analyses will be used to study molecular mechanisms of response and resistance to BTK degraders, particularly in patients previously treated with BTK and BCL-2 inhibitors. The cohort is led by Nantes University Hospital with sample collection at participating centers in Angers and Bordeaux, France.
Who should consider this trial
Good fit: Adults with CLL who are candidates for or have been treated with BTK degrader drugs, can give informed consent, and are covered by French social security are eligible.
Not a fit: Children, adults under guardianship, and other legally protected persons are excluded and are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the biobank could identify biomarkers that predict response or resistance to BTK degraders and guide better treatment choices for CLL patients.
How similar studies have performed: Biobanking and molecular studies have previously identified resistance mechanisms to BTK inhibitors, but applying these methods specifically to the new class of BTK degraders is novel and early-stage.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with CLL candidates ou exposed to BTKd * Patient who has provided informed consent to participate in the study. * Patient covered by a social security health insurance plan Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons.
Where this trial is running
Angers and 13 other locations
- CHU de Angers — Angers, France (Not_yet_recruiting)
- CHU de Bordeaux — Bordeaux, France (Not_yet_recruiting)
- Institut Bergonié — Bordeaux, France (Not_yet_recruiting)
- CHU de Clermont-Ferrand — Clermont-Ferrand, France (Not_yet_recruiting)
- CHD Vendée — La Roche-sur-Yon, France (Not_yet_recruiting)
- Centre Léon Bernard — Lyon, France (Not_yet_recruiting)
- Institut Paoli-Calmettes (Marseille) — Marseille, France (Not_yet_recruiting)
- CHU de Montpellier — Montpellier, France (Not_yet_recruiting)
- CH Régional Universitaire de Nancy — Nancy, France (Not_yet_recruiting)
- University Hospital — Nantes, France (Recruiting)
- Hôpital Avicenne (AP-HP) — Paris, France (Not_yet_recruiting)
- Hôpital Universitaire Pitié Salpêtrière de Paris — Paris, France (Not_yet_recruiting)
- CHU de Poitiers — Poitiers, France (Not_yet_recruiting)
- Centre Henri-Becquerel de Rouen — Rouen, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Anne LOK, MD, PhD — Hospital of Nantes
- Study coordinator: ANNE LOK, Dr
- Email: anne.lok@chu-nantes.fr
- Phone: 02.40.08.42.11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.